There's a New Threat to the Stock Market and President Donald Trump's Economy
Source: The Motley Fool
The article warns that the FOMC's rate-hiking cycle, initiated Sept. 16, could derail the AI infrastructure-driven equity rally by raising financing costs for debt-funded data-center investment. Corporate debt issuance reached a record $2.64 trillion over the past 12 months, while non-T-bill Treasury issuance rose to $5.06 trillion, intensifying competition for capital. With stocks entering 2026 at their second-highest valuation in nearly 156 years, a slowdown in AI spending or contraction in M2 liquidity could trigger a valuation reset and pressure the broader U.S. economy.
Analysis
The relevant transmission mechanism is not an outright demand collapse for AI silicon, but a higher discount rate applied to long-duration earnings while hyperscalers reassess marginal data-center returns. NVDA is more exposed to a multiple reset than a near-term revenue shortfall because its order book is largely funded by cash-rich customers; MU has greater two-way risk, since HBM pricing remains tight but conventional DRAM/NAND utilization can weaken rapidly if enterprise spending decelerates. The better relative short is the levered AI infrastructure tail—networking, power, cooling and smaller GPU-cloud operators—where project financing and customer concentration make deferred capex immediately visible.
The article overstates the mechanical link between policy rates and M2. Deposit migration, Treasury cash management, bank reserve conditions and fiscal deficits can dominate broad-money growth, so monthly M2 data are a poor standalone trading trigger. The more actionable 1-3 month indicators are hyperscaler capex guidance, AI-server lead times, HBM contract pricing, 10-year real yields, and credit spreads; a rise in real yields without capex cuts is likely a valuation event rather than an earnings impairment.
Contrarianly, a modest tightening cycle could improve the quality of AI spending by forcing capital discipline, consolidating demand toward NVDA and MU's highest-return products while impairing weaker competitors. Over 6-18 months, constrained financing would favor incumbent semiconductor leaders with net cash, pricing power and secured supply, but the current premium leaves little tolerance for even a small guide-down. A break in HBM pricing or a material hyperscaler capex deferral—not M2 alone—would falsify the relative-long thesis.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.42
Ticker Sentiment
Key Decisions for Investors
- Maintain a 1-3 month quality pair: long NVDA / short an AI-infrastructure basket proxy such as ARKK or SMH versus equal notional only after confirming rising 10-year real yields and no upward revision to hyperscaler capex. Target 10-15% relative return; exit if NVDA guides data-center revenue below consensus or real yields fall more than 40bp.
- Prefer MU over lower-quality memory beta for a 6-12 month horizon, but size modestly until quarterly HBM pricing and bit-demand data confirm supply tightness. Use a stop on a meaningful sequential gross-margin guide-down; upside depends on HBM mix offsetting any commodity-memory downturn.
- Buy 3-6 month QQQ put spreads rather than outright index shorts if rates continue higher: this captures multiple-compression risk while limiting loss if AI earnings remain resilient. Initiate only if QQQ holds near highs while 10-year real yields make new cycle highs; target a 7-10% Nasdaq drawdown.
- Do not trade NFLX or GETY on this signal. Their inclusion lacks a clear rate-to-fundamental transmission mechanism; revisit NFLX only if consumer credit stress or advertising-demand revisions emerge.
More News
- Bond market alarms are ringing on Wall Street. Here's what's ahead
- Microsoft gives Copilot a much-needed overhaul, and the stock deservedly soars
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Why Microsoft Stock Is Up Today
- U.S. appeals court upholds Pentagon designation of Anthropic as supply chain risk
- Why Akamai Stock Is Up Today